Gerald Andriole, MD

Chief Medical Officer, Prostatype Genomics

[Gerald Andriole, MD @uropro]

Finally an improved biopsy needle! #Xagasurgical #AUA2026 #Booth2863
Better targeting and reduced bacterial transfer

[Laura Caba @Caba_L]

A toast 🥂 to the 50th Anniversary of the Winter Urologic Forum! 💫

Always a great meeting!

@ColumbiaUrology @UCDavisUrology
Vanderbilt Urology

[UroToday.com @urotoday]

Phase 1 study evaluates bone metastasis resolution with SYNC-T therapy SV-102. @uropro @ProstatypeAB joins @zklaassen_md @GACancerCenter SYNC-T therapy SV-102 for metastatic prostate cancer. The treatment combines one-minute cryolysis of tumor tissue with immediate infusion of a four-component immunoadjuvant to generate tumor-specific T cell responses. #WatchNow > https://t.co/MA84sV19hq

[Gerald Andriole, MD @uropro]

@dr_coops @PathNetLab @UrologyUS Amazing technology!

[Gerald Andriole, MD @uropro]

Prostatype P-score demonstrated superb risk classification of Prostate Cancer in a diverse US population. Very useful tool for men considering Active Surveillance and the intensity of surveillance. Low risk men had no PCSM! @nature.com/pcan/

[Gerald Andriole, MD @uropro]

@urotoday @ProstatypeAB @zklaassen_md Xxxxz x cczz.?x S

[Gerald Andriole, MD @uropro]

@urotoday @ProstatypeAB @zklaassen_md C

[Syncromune® @syncromune]

Thank you #SUO25. We were proud to share Phase 1 SYNC-T data showing 54% of metastatic prostate cancer patients had complete resolution of bone metastases and favorable tolerability.
SYNC-T is now being studied for mCRPC in the Phase 2 LEGION-100 trial.
Details: https://t.co/B77FgCurNq

[Julian Chavarriaga @chavarriagaj]

#SUO25 @uropro presents SYNC-T SV-102 for mPCa
🧬 Image-guided intratumoral immunotherapy targeting 4 immune axes
👥 n=15 (Phase 1) | post-ARPI or hormone-declined | bone mets in 87%
🔹 ORR: 87% | CR: 53%
🔹 Bone mets resolved in 7/13 pts incl. >50 lesions in 1 case
🛡️ 95% Grade 1–2 AEs | no Gr 4/5
✅ Early signal for durable, systemic immunity via local delivery
@UroToday @UroOnc

[Syncromune® @syncromune]

Syncromune® Inc. Presents Positive Results from SYNC-T® Therapy SV-102 Phase 1 Metastatic Prostate Cancer Trial at ASCO 2025
- 87% ORR
- 53% CR
- 100% DCR
- 14.2 months rPFS
- 80% survival after 17.2 month median follow-up
https://t.co/7RwjvEI6Gd

[Syncromune® @syncromune]

Stop by the Syncromune booth at #ASCO25 to learn more about our LEGION-100 Phase 2a trial of SYNC-T Therapy SV-102 for #mCRPC. Now enrolling and recruiting clinical trial sites. #LEGION100 #ProstateCancer

[Syncromune® @syncromune]

Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting #ASCO25 https://t.co/pSccGXxVNd

[Laura Caba @Caba_L]

So inspired to be collaborating with an incredible team of experts in bladder cancer. Excited for the impactful work we’ll do together transforming early detection!

https://t.co/Dd9B3EdJmS

@UroCancerMD @pcvblack @SimaPorten @siadaneshmand @ctleeuro @garysteinbergmd @ylotan

[Gerald Andriole, MD @uropro]

@elonmusk .

[Gerald Andriole, MD @uropro]

Prostatype Genomics receives CAP laboratory accreditation, achieves another milestone towards entering the US market https://t.co/QCdBkdTsTd

[Gerald Andriole, MD @uropro]

Prostatype Genomics AB US subsidiary Prostatype Genomics, Inc. has been accredited by the CAP (College of American Pathologists) Laboratory Accreditation Program!

[Gerald Andriole, MD @uropro]

Dr. Gerald Andriole presented Prostatype Genomic Classifier's ability, with a significant AUC of .88 (Gleason score ≥4+3and/or pT3), to predict adverse pathology at RP.
📷

[STLToday Sports News @STL_SportsNews]

Gordo ranks area hoops: Cloud forms over Illinois, SLU gets huge boost https://t.co/5YmoEAvsU4

[FOCAL+ 2025 @therapy_focal]

#FOCAL2023 starts TOMORROW! Make sure to follow all of our awesome faculty!

@arvinkgeorge @AbhinavSidana @Freddie_Hamdy @DrJohnMDiBi @uropro @LetDdiceFlyHigh @ezebecher @DrSteveCanfield @peterchiu_uro @ChughtaiMD @BehfarEhdaieMD @FryeUroOnc @gupta_go @amy_krambeck @fleauxdoc @oncostan @lissmike @RaisBahrami @Rowe_NuclearMed @TaimurShah @DrilyaSobol1 @Dr_sprenkle @tanejauro @radiolobt @vermasadhna @vourganti @Dr_KevinZorn

[Keith Kowalczyk, MD @KeithKow]

Please join myself with @MGuptaMD @RossKrasnow @MaxKates @KGUROmd @NathanShawMD @apolo_andrea @uropro @RyanWerntzMD @UroOncDC and more for two days of urologic oncology knowledge in our nation’s capital!

https://t.co/dUF0oMrdCB

@MedStarHealth @LombardiCancer @GUUrology